REVIEW - NEW DIRECTIONS IN THE OPTIMIZATION OF OCULAR DRUG DELIVERY

被引：56

作者：

LEE, VHL

机构：

[1] University of Southern California, School of Pharmacy, Los Angeles, CA

来源：

JOURNAL OF OCULAR PHARMACOLOGY | 1990年 / 6卷 / 02期

关键词：

D O I：

10.1089/jop.1990.6.157

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The main effort in ocular drug delivery during the past two decades has been on the design of systems to prolong the residence time of topically applied drugs in the conjunctival sac. Four recent developments promise to chart a new course in ocular drug delivery research: collagen shield as a topical ocular drug delivery system, in-situ activated gel-forming systems, noncorneal route of ocular drug penetration, and need for minimizing the systemic absorption of topically applied drugs. © 1990, Mary Ann Liebert, Inc. All rights reserved.

引用

页码：157 / 164

页数：8

共 46 条

[31] Wood R.W., Li V.H.K., Kreuter J., Robinson J.R., Ocular disposition of poly-hexyl-2-cyano[3- 14C]acrylate nanoparticles in the albino rabbit, Int. J. Pharm, 23, pp. 175-183, (1985)
[32] Diepold R., Kreuter J., Himber J., Gurny R., Lee V.H.L., Robinson J.R., Saettone M.F., Schnaudigel O.E., Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops and a novel depot formulation (nanoparttcles), Graef's Arch, Clin. Exp. Ophthalmol, 227, pp. 188-193, (1989)
[33] Kaila T., Huupponen R., Salminen L., Effects of eyelid closure and nasolacrimal duct occlusion on the systemic absorption of ocular timolol in human subjects, J. Ocular Pharmacol, 2, pp. 265-269, (1986)
[34] Polansky J.R., Alvarado J.A., Isolation and evaluation of target cells in glaucoma research: hormone receptors and drug responses, Curr, Eye Res, 4, pp. 267-279, (1985)
[35] Wandel T., Charap A.D., Lewis R.A., Partamian L., Cobb S., Lue J.C., Novak G.D., Gaster R., Smith J., Duzman E., Glaucoma treatment with once-daily levobunolol, Am. J. Ophthalmol, 101, pp. 298-304, (1986)
[36] Coleman A.L., Robin A.L., Pollack I.P., Rudikoff M.T., A comparison of the cardiovascular effects and intraocular pressure lowering of apraclonidine and timolol, Invest, Ophthalmol. Vis. Sci, 30, (1989)
[37] Stein H.H., Giardina W.J., Ebert D.M., Cohen J., Condon S., Fung A.K.L., Kleinert H.D., Luly J.R., Plattner J.J., Rosenberg S.H., Woods K., The lowering of intraocular pressure (I0P) in rabbits by topical application of renin inhibitors, The Pharmacologist, 31, (1989)
[38] Chang S.C., Lee V.H.L., Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption, J. Ocular Pharmacol, 3, pp. 159-169, (1987)
[39] Luo A.M., Heuer D.K., Lee V.H.L., Pharmacokinetic basis for the non-additivity in intraocular pressure lowering of topically applied timolol-epinephrine combinations in the pigmented rabbit, Invest, Ophthalmol. Vis. Sci, 31, (1990)
[40] Chang S.C., Chein D.S., Bundgaard H., Lee V.H.L., Relative effectvveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol, Exp, Eve Res, 46, pp. 59-69, (1988)

← 1 2 3 4 5 →